Boeing at risk of losing a third of new 777X aircraft orders due to delays: Report
Wide-body jets such as the Boeing 777X, Boeing 787 Dreamliner and Airbus SE models, are among the products likely to recover last from the demand hit of the COVID-19 pandemic.
Inside of a Singapore Airlines Boeing 787-10 Dreamliner (Representative image - REUTERS/Randall Hill)
Boeing may be at risk of losing a third of its 777X orders as the aircraft’s debut was pushed back yet again to late 2023. The delay gives customers the right to break the contract, Bloomberg reported.
The United States-based aircraft manufacturer in a regulatory filing on February 1 said it has a backlog of 191 jets from the 777X family – a 38 percent lower backlog that the number listed on its website, the publication noted.
Company s 52-week low was at $23.63
Price action over last quarter: Up 6.76%
Company Overview
PJT Partners Inc is a United States-based company that focuses on advisory business. The company s core businesses include the strategic advisory business, which provides financial advisory and transaction execution capability; the business of restructuring and special situations, which offers advisory services on recapitalizations, reorganizations, debt repurchases, exchange offers, capital raises, and distressed mergers and acquisitions; and the fund placement and secondary advisory business, which offers fund placement and secondary advisory services. The company generates its revenue from the advisory fee, placement fee, and others. Geographically, It generates a majority of revenue from the U.S., with the rest from overseas markets.
Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States
February 02, 2021 14:21 ET | Source: Medexus Pharmaceuticals Inc Medexus Pharmaceuticals Inc
Orphan Designated Drug with August 2021 PDUFA date
Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and
Key Opinion Leader webinar to be held at 2:00 PM Eastern Time on February 5, 2021
TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) Medexus Pharmaceuticals Inc. (“
Medexus”) (TSXV: MDP) (OTCQX: MEDXF)
(Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“
Company Overview
Powell Industries Inc is a United States-based company that develops, designs, manufactures, and services custom-engineered equipment and systems for electrical energy distribution, control, and monitoring. The company s principal products comprise integrated power control room substations, custom-engineered modules, electrical houses, traditional and arc-resistant distribution switchgear and control gear, and so on. These products are applied in oil and gas refining, offshore oil and gas production, petrochemical, pipeline, terminal, mining and metals, light-rail traction power, electric utility, pulp and paper, and other heavy industrial markets. The company generates the majority of its sales from the United States.
The Mohegan Tribal Gaming Authority has had its corporate family rating for debt raised to ‘Caa1’ with a ‘stable’ outlook, from ‘Caa2’, by Moody’s Investors Service Inc. The Mohegan Tribal Gaming Authority controls United States-based tribal casino operator Mohegan Gaming and Entertainment, a group with investment in Asia.
The ratings institution also improved the authority’s ‘probability of default’ rating to ‘Caa1-PD’ from ‘Caa2-PD’.
According to Moody’s, obligations rated ‘Caa’ are “judged to be speculative of poor standing and are subject to very high credit risk”.
Moody’s states that corporate family ratings classified as ‘Caa-PD’, are “judged to be speculative of poor standing subject to very high default risk, and may be in default on some but not all of their long-term debt obligations”.